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Abstract
Aims Non-invasive telemonitoring (TM) in patients with heart failure (HF) and reduced left ventricular ejection fraction
(HFrEF) may be useful in the early diagnosis of HF decompensation, allowing therapeutic optimization and avoiding
re-hospitalization. We describe a TM programme in this population and evaluate its effectiveness during a 12 month period.
Methods and results We conducted a single-centre study of patients discharged from hospital after decompensated HF,
allocated into three groups: prospective TM programme, prospective HF protocol follow-up programme (PFP) with no TM
facilities, and retrospective propensity-matched usual care (UC). TM effectiveness was assessed by all-cause hospitalizations
and mortality; HF-related hospitalization (HFH), days lost to unplanned hospital admissions/death, functional capacity and
quality of life (New York Heart Association, Kansas City Cardiomyopathy Questionnaire, 6 min walk test, and plasma
N-terminal pro-brain natriuretic peptide) were also evaluated. A total of 125 patients were included [65.9 ± 11.9 years, 32%
female, left ventricular ejection fraction 27% (21–32)]. TM was similar to PFP regarding effectiveness; TM reduced all-cause
hospitalization and mortality (HR 0.27; 95% CI 0.11–0.71; P < 0.01) and HFH (HR 0.29; 95% CI 0.10–0.89; P < 0.05) as compared
with UC. TM reduced the average number of days lost due to unplanned hospital admissions or all-cause death as compared
with PFP (5.6 vs. 12.4 days, P < 0.05) and UC (5.6 vs. 48.8 days, P < 0.01). Impact on quality of life was similar between TM and
PFP (P ¼ 0.36).
Conclusions In patients with HFrEF and recent HF hospitalization, non-invasive TM reduced 12 month all-cause
hospitalization/mortality and HFH as compared with usual care. TM also reduced the number of days lost due to unplanned
hospital admission/death as compared with either an optimized protocol-based follow-up programme or usual care.
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Introduction
Heart failure (HF) affects 2% of the adult population.1 Even
though post-discharge programmes with multidisciplinary
teams have proved to reduce all-cause re-hospitalizations
and mortality and to be cost saving,2–4 HF still contributes
annually to all-cause mortality rates of 17% and to hospitali-
zation rates of 44%.5
Driven by the development of new technologies, telemed-
icine is substantially growing,6 allowing, among other things,
the provision of patients’ physiological parameters to health
care professionals. It may represent a disruptive innovation
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in the early diagnosis of HF decompensation and in the
follow-up of chronic HF patients. Remote invasive monitoring
has demonstrated to reduce the risk of recurrent HF
hospitalization7,8 with a favourable cost-effectiveness9,10 pro-
file, leading to its inclusion in the 2016 European Society of
Cardiology guidelines as a class IIb recommendation, level
of evidence B.11 However, considering the non-invasive mon-
itoring in HF patients, there is lack of data and conflicting re-
sults among studies.11–15
Most recently, the Telemedical Interventional Manage-
ment in patients with heart failure (TIM-HF2) trial demon-
strated that a structured remote patient management
intervention, when used in a well-defined HF population,
could reduce the percentage of days lost due to unplanned
cardiovascular (CV) hospital admissions and all-cause
mortality.16 In the 2019 consensus document on clinical prac-
tice update on HF, a similar approach to the one used in
TIM-HF2 may be considered to reduce the risk of recurrent
CV and HF hospitalizations and the risk of CV death.17
However, real-world data on prognostic impact of
non-invasive remote monitoring are very limited, and the
best follow-up approach to manage these patients is yet to
be established. We conducted a prospective study in a
real-practice context to assess the feasibility and effective-
ness of a telemonitoring (TM) programme in reducing hospi-
talization and mortality in a population with HF and reduced
ejection fraction (HFrEF) considered at high risk for hospital
readmission.
Methods
Study design and objectives
The study was prospective with a control retrospective group
of patients hospitalized for acute (decompensated) HFrEF at
the cardiology department of a tertiary hospital (Centro
Hospitalar Universitário Lisboa Norte, Lisbon, Portugal). Pa-
tients were included in the study after discharge from the
cardiology ward. The groups were propensity matched.
The study was performed according to the principles
outlined in the Declaration of Helsinki and the Good Clinical
Practice guidelines of the European Commission. All patients
provided written informed consent, and the study protocol
was approved by the institutional ethics committee (Refer-
ence Number 389/17).
The main objective was to evaluate the effectiveness of a
TM programme in the follow-up of patients with HFrEF. Effec-
tiveness was quantified by a composite endpoint of all-cause
mortality or all-cause hospitalization. Additional study objec-
tives included evaluation of HF-related hospitalization, days
lost due to unplanned hospital admissions or death, func-
tional capacity, and quality of life. Functional capacity and
quality of life were assessed on a 6 month basis according
to the New York Heart Association (NYHA) classification,
N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma
levels, Kansas City Cardiomyopathy Questionnaire (KCCQ)18
score, and 6 min walk test (6MWT).
Study population
We included adult male or female patients ≥ 18 years of age
with HFrEF (EF ≤ 40%) who had at least one hospital admis-
sion due to HF decompensation in the previous 12 months.
We excluded patients with cardiogenic shock in the previ-
ous 4 weeks, with heart surgery in the previous 8 weeks, on
the waiting list for cardiac transplant, on haemodialysis, or
that had psychiatric or cognitive impairments that
constrained the understanding and utilization of telehealth
devices.
After hospital discharge from the cardiology ward, three
groups of patients were considered: (i) patients followed up
prospectively with the support of non-invasive TM facilities
(between December 2017 and December 2018); (ii) patients
followed up prospectively accordingly to a protocol-based
HF follow-up programme (PFP) but with no TM (between
April 2016 and November 2017), and (iii) patients followed
up according to the usual care practice (retrospective data),
who were discharged before the implementation of the PFP
or TM programmes (between April 2015 and April 2016). Pa-
tients were matched according to age, NYHA functional class
at discharge, and left ventricular ejection fraction (LVEF).
Interventions
Patients assigned to the TM programme (TM group) were
provided with home-monitoring devices to evaluate blood
pressure, heart rate, peripheral oxygen saturation, body
weight, total body water content, body temperature, daily
walking steps, and three-lead electrocardiogram (ECG).
Figure 1 illustrates the flowchart of the TM programme man-
agement. Further details are available in Data S1. Measure-
ments were evaluated on a daily basis during the first week
in the programme and after any acute event (e.g. hospitaliza-
tion or visit to the emergency department for worsening HF).
Otherwise, measurements were taken three times per week
on alternate days. The ECG was performed once a week. A
clinical monitoring centre (CMC), which included nurses,
pharmacists, and cardiopneumology technicians, monitored
the biodata. Biodata transmission was set at a fixed time,
but patients were free to contact the CMC directly at any
time (24/7) using the mobile phone provided for data trans-
mission. At the beginning of the TM programme, the biodata
baseline settings were defined for each patient, as well as the
respective personalized alarm threshold. Whenever two or
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more parameters were abnormal to any individual patient, an
alert for a potential HF decompensation was triggered, CMC
contacted the patient for more detailed information, and
the adapted Portuguese version of the Morisky Medication
Adherence Scale19,20 was applied. When the alert was con-
firmed, the CMC contacted the cardiologist on duty for the
TM programme reporting the altered biodata and patients’
symptoms. According to the severity of HF decompensation,
a personalized action was taken, which might include therapy
optimization, at-home plasma NT-proBNP measurement,
non-programmed medical appointment, or referral to the
emergency department. In the absence of biodata measure-
ment by the patient or difficulties in remote transmission of
data, a technical alert was generated, and the CMC contacted
the patient.
Patients included in the protocol-based follow-up pro-
gramme (PFP group) had appointments at the hospital with
the assistant cardiologist at the 7–10th day, 1st, 3rd, 6th,
and 12th months after discharge (and additionally, whenever
considered necessary) with clinical, laboratory, and ECG eval-
uations. Patient education and therapeutic optimization were
pursued in accordance with European Society of Cardiology
recommendations.21
Patients included in the usual care group (UC group) were
followed up according to the assistant physician (cardiologist
and/or GP) that included clinical, laboratory, ECG evaluation,
and therapeutic optimization at physician’s discretion.
Statistical analysis
Assuming that the estimated annual rate of all-cause mortal-
ity or all-cause hospitalization would be 65% in the control
group (usual care) and 25% in the study group (TM) with
an enrolment ratio of 2 (based on HF populational
studies5,22 and TM programme studies, TIM-HF,13 respec-
tively), it was estimated that 34 patients would need to be
followed up in usual care and 17 in TM for 12 months to
provide the study with a power of 80% to detect a signifi-
cant relative reduction in the risk of all-cause mortality or
all-cause hospitalization in the TM programme group, at an
overall two-sided α level of 0.05.
Continuous variables were presented as mean ± standard
deviation or median with interquartile range, as appropriate.
Comparisons between patient groups were performed on
continuous variables using the unpaired Student’s t-test or
Mann–Whitney test, as appropriate. Normality was assessed
using the Kolmogorov–Smirnov test. Non-parametric
Kruskal–Wallis test was performed to compare baseline char-
acteristics between the three groups. Categorical variables
FIGURE 1 Flowchart of the organization of the Telemonitoring programme.CMC, clinical monitoring centre; HF, heart failure.
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were compared using χ2 tests. Paired comparisons at differ-
ent time-points were performed using the Wilcoxon test.
Freedom from all-cause mortality or hospitalizations was
evaluated with the Cox proportional hazards model and
Kaplan–Meier analysis, with the hazard ratio and 95% confi-
dence interval (CI) reported.
Days lost due to unplanned hospital admission or death
were calculated as the number of days lost due to hospital
emergency department visit (1 day was considered if hospi-
talization was not carried out) or the total number of days
the patient stayed in-hospital divided by the intended
follow-up of 365 days. For patients who died, the number
of days lost between the date of death and the date of
intended follow-up plus the number of days spent in hospi-
tal was counted.
For statistical tests, P < 0.05 was considered statistically




In total, 125 patients with HFrEF were included: 25 patients
assigned for non-invasive TM (TM group), 50 patients
assigned for the protocol-based follow-up programme (PFP
group) with no TM facilities, and 50 patients assigned for
the usual care follow-up (UC group). From the initial 26 pa-
tients screened for the TM follow-up, one patient was ex-
cluded owing to difficulties in the management of
non-invasive devices.
Overall, mean age of patients was 65.9 ± 11.9 years, and
32% were female. Idiopathic dilated cardiomyopathy was the
main aetiology of HF, median LVEF at baseline was 27% (21–
32), andmeanNT-proBNPwas 3085 ± 3228 pg/mL. There were
no significant differences in the baseline clinical and laboratory
characteristics of patients of the three groups (Table 1).
Table 1 Baseline characteristics of the study population
TM group (n ¼ 25) PFP group (n ¼ 50) UC group (n ¼ 50) P value
Age (years), mean ± SD 65.4 ± 9.7 67.5 ± 11.0 64.58 ± 13.73 0.98
Female gender, n (%) 8 (32) 13 (26) 19 (38) 0.44
NYHA class, n (%)
I 5 (20) 15 (30) 20 (41) 0.08
II 16 (64) 32 (64) 27 (55)
III 4 (16) 3 (6) 3 (4)
IV 0 (0) 0 (0) 0 (0)
LVEF, median (IQR) 26 (21–30) 26.5 (19.8–34.3) 27.5 (21.8–31.3) 0.27
HF aetiology, n (%)
Idiopathic DCM 14 (56) 26 (52) 23 (46) 0.90
Ischemic CMP 10 (40) 18 (36) 20 (40)
Valvular CMP 1 (4) 4 (8) 5 (10)
Other 0 (0) 2 (4) 2 (4)
Laboratory data
Serum creatinine (mg/dL) 1.23 ± 0.58 1.23 ± 0.45 1.32 ± 0.48 0.35
NT-proBNP, pg/mL 3112 ± 2456 3394 ± 4043 2959 ± 3097 0.50
Co-morbidities, n (%)
Hypertension 17 (68) 36 (72) 35 (70) 0.94
Diabetes 9 (36) 19 (38) 28 (56) 0.12
Anaemiaa 6 (24) 10 (20) 12 (24) 0.87
CKDb 12 (48) 23 (46) 27 (54) 0.95
CPD 8 (32) 20 (40) 22 (44) 0.66
Atrial fibrillation 8 (32) 27 (54) 25 (50) 0.19
Medical therapy, n (%)
ACEi/ARB/ARNi 25 (100) 48 (96) 47 (94) 0.58
Beta-blocker 25 (100) 48 (96) 48 (96) 0.60
MRA 24 (96) 43 (86) 42 (84) 0.32
Diuretic 19 (76) 44 (88) 42 (84) 0.41
ICD 13 (52) 18 (36) 15 (30) 0.18
CRT 7 (28) 11 (22) 14 (28) 0.75
ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; CKD,
chronic kidney disease; CMP, cardiomyopathy; CPD, chronic pulmonary disease; CRT, cardiac resynchronization therapy; DCM, idiopathic
dilated cardiomyopathy; HF, heart failure; HTN, systemic arterial hypertension; ICD, implantable cardioverter defibrillator; LVEF, left ven-
tricular ejection fraction; MRA, mineralocorticoid-receptor antagonist; n, number; NYHA, New York Heart association functional class; PFP,
protocol-based follow-up programme group; SD, standard deviation; TM, telemonitoring group; UC, usual care (UC) group.
aHaemoglobin < 12 g/dL (women) and <13 g/dL (men).
bEstimated glomerular filtration rate < 60 mL/min/1.73 m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration
formula).
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Effectiveness
At 12 months, the composed outcome of all-cause mortality
or all-cause hospitalization occurred in 5/25 patients (20%)
in the TM group, in 17/50 patients (34%) in the
protocol-based follow-up programme group, and in 28/50 pa-
tients (56%) in the usual care group (Figure 2).
There was no difference between TM and PFP groups re-
garding the effectiveness outcome (HR 0.54, P ¼ 0.2). TM sig-
nificantly reduced all-cause mortality or all-cause
hospitalization when compared with UC (HR 0.27; 95% CI
0.11–0.71; P < 0.01), with a relative risk reduction of 73%
and a number needed to treat to prevent one hospitalization
or death of 3.
Hospitalization and mortality
There was no difference between TM and PFP regarding HF
hospitalizations (P ¼ 0.4). TM, when compared with the UC,
significantly reduced the rate of HF-related hospitalization
(12% vs. 36%, HR 0.29; 95% CI 0.10–0.89; P < 0.05) and
all-cause hospitalizations (HR 0.29; 95% CI 0.11–0.75;
P < 0.001).
Regarding all-cause mortality, one of 25 (4%) patients in
the TM group, two of 50 (4%) patients in the PFP group,
and eight of 50 (16%) in the UC group died, with no differ-
ences between groups.
Days lost due to unplanned hospital admission or
death
Nine out of the 25 patients (36%) assigned for TM, 32 out
of the 50 patients (64%) assigned for PFP, and 34 out of
the 50 patients (68%) assigned for UC were admitted to
hospital for an unplanned reason or died during the
12 month follow-up; 163 unplanned hospital admissions
were reported, with a total of 3201 days lost to unplanned
hospital admissions or death.
Patients in the TM group lost an average of 5.6 days per year
compared with 12.4 days lost in the PFP group and 48.8 days in
the UC group. There was a reduction in the average of days lost
due to unplanned hospital admissions or all-cause death in the
TM group compared with PFP group (5.6 vs. 12.4 days,
P < 0.05) and compared with UC (5.6 vs. 48.8 days, P < 0.01;
Figure 3). The percentage of days lost due to unplanned hospi-
tal admission or death per year was 1.5%, 3.4%, and 13.3%, re-
spectively, for TM, PFP, and UC groups.
FIGURE 2 Effectiveness endpoint—cumulative all-cause hospitalization or all-cause mortality rate in telemonitoring (TM) group, usual care (UC) group,
and protocol-based follow-up programme (PFP).
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Functional capacity and quality of life
At 12 months, TM group demonstrated a higher NYHA class
improvement than PFP group (52.2% vs. 32%, P < 0.05) and
UC group (52.2% vs. 16%, P < 0.001). Key outcomes on func-
tional capacity and quality of life are presented in Table 2.
There was a significant reduction in the mean NT-proBNP
plasma value during the 12 month follow-up both in the TM
and PFP groups (from 3112 ± 2456 to 1655 ± 1670 pg/mL
and from 3394 ± 4043 to 3183 ± 7170 pg/mL, respectively).
In the UC group, there was a non-significant increase in
NT-proBNP (from 2959 ± 3097 to 3009 ± 1241 pg/mL,
P ¼ 0.60).
The mean increase in total symptom score in the KCCQ (in-
dicating fewer symptoms) for 12 months was similar in the
TM and PFP groups (19.9 ± 26.2 vs. 13.5 ± 21.1, P ¼ 0.36).
According to 6MWT results, patients in the TM group im-
proved from an average of 316 m at baseline to 417 m at
12 months (P < 0.001).
Patient’s compliance with telemonitoring
For patients assigned to the remote monitoring programme,
at 12 months, 92% were compliant with the transfer of at
least one parameter and 88% were at least 75% compliant
with the transfer of all required data according to the proto-
col; 33641 vital parameters [median of 1293 per patient
(120–1806)], with a total of 3168 alerts (1360 clinical alerts),
were transmitted to the CMC during this period.
Discussion
In this study, we presented a modified method of follow-up
of patients with chronic HFrEF at high risk for HF readmission,
complementing the medical follow-up with technological fa-
cilities as non-invasive TM. This feasible model of
non-invasive remote monitoring reduced all-cause
Table 2 Outcomes related to functional capacity and quality of life
Key secondary outcomes TM group PFP group UC group
NYHA functional class
Improvement, % 52.2 32 16
Unchanged, % 28 52 46
Worsened, % 19.8 16 38
Change in KCCQ total symptom score 19.9 ± 26.2 13.5 ± 21.1 NA
Change in NT-proBNP from baseline to 12 months of follow-up 47% (P ¼ 0.014) 6.2% (P ¼ 0.019) 1.7% (P ¼ 0.6)
Change in 6MWT from baseline to 12 months of follow-up 31.8% (P < 0.001) NA NA
6MWT, 6 min walk test; KCCQ, Kansas City Cardiomyopathy Questionnaire; NA, not applicable (see text for details); NT-proBNP, N-terminal
pro-brain natriuretic peptide.
FIGURE 3 Number of days lost due to unplanned hospital admission or death during a 12 month follow-up. PFP, protocol-based follow-up programme;
TM, telemonitoring group; UC, usual care group. * P < 0.01; ** P < 0.05.
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hospitalization/mortality (20% vs. 56%, P < 0.01) and HF hos-
pitalization (12% vs. 36%, P < 0.05) compared with the usual
care, during a 12 month period. It also reduced the number
of days lost due to unplanned hospital admission or death
compared either to usual care (5.6 vs. 48.8 days, P ¼ 0.001)
or to an optimized protocol-based follow-up programme
(5.6 vs. 12.4 days, P < 0.05).
TM programmes have shown controversial results due to
the diverse methodologies employed and the heterogeneity
of the HF populations included.11,12,16 As congestion is the
most frequent cause for HF decompensation,23 monitoring
of bio-signals may be important to detect it and optimize
medical therapy, preventing hospital admission to the emer-
gency department or even a hospitalization. Some of the ma-
jor barriers in implementing TM with favourable results may
include the target population and its compliance to the pro-
gramme. TIM-HF2 study16 included patients with at least
one HF hospitalization in the 12 months preceding enrol-
ment, and we hypothesized that this could have been one
of the reasons why the programme reduced the percentage
of days lost due to unplanned CV hospital admissions and
all-cause mortality, as patients with recent hospitalizations
from acute HF have a higher risk of decompensation in the
vulnerable period.24 In addition, TIM-HF2 study also excluded
patients with major depression to strengthen adherence to
the protocol. In fact, patient’s compliance is a key point in
any TM programme, because a low compliance may jeopar-
dize the benefits of such monitoring, as it was observed in
the TM in patients with Heart Failure trial (Tele HF12).
In the study presented herein, the benefits of TM were
demonstrated compared with those of UC in HFrEF patients
with a recent HF hospitalization and thus at a high risk of de-
compensation. Even though the effectiveness of TM was sim-
ilar to PFP, it must be considered that patients on the PFP (all
with optimized HF therapy) had at least five medical appoint-
ments in a 12 month period. Additionally, most patients
benefited from a direct phone contact to his/her HF specialist
in case of any potential decompensation, which may have
smoothened the differences between TM and PFP. In fact,
TM, when compared with PFP, reduced the number of days
lost due to unplanned hospital admission or death. The impact
of TM on this outcome demonstrates the importance of the
programme in the reduction of emergency department visits,
hospitalizations, and mortality. A longer time with no need for
hospital care highlights the real-life impact of such pro-
gramme in the quality of life of patients living with chronic HF.
On the other hand, compliance of patients to remote mon-
itoring was fundamental to the positive results observed. At
the beginning of the TM programme, data were undertaken
on a daily basis implying a heavy burden on patients and care-
givers. With that awareness, after 2 months from the start of
the programme, we adapted the protocol to measure
bio-signals daily during the first week in the programme or af-
ter any decompensation and only three times a week on
alternate days thereafter, reducing the burden of monitoring
that kept patients’ adherence to the programme, with no sig-
nificant differences in the outcomes. The frequent monitoring
of biodata may have also improved patients’ awareness re-
garding HF and improved their disease self-management. In
fact, the high rate of patients’ adherence may be a recogni-
tion of the impact of TM in their prognosis and quality of life.
Overall, the favourable prognostic impact of TM may come
from the early diagnosis of a potential HF decompensation
driving a prompt personalized treatment, within a
well-structured workflow. The critical problem is not the ac-
curately acquisition and transmission of biodata but the dis-
tinction between noise and true clinical alert. Artificial
intelligence may potentially overcome this problem, helping
in medical decisions in the future.6
Finally, with the increasing prevalence of HF and limited
medical resources, TM may be an effective tool to decen-
tralize patients from hospitals, whilst maintaining their re-
mote follow-up, self-awareness of the disease, and
patient–doctor empathetic relationship. The positive results
observed in our study should be followed by a
cost-effectiveness analysis.
Limitations
This was a prospective study with retrospective data regard-
ing the matched UC group. Thus, retrospective data retrieval
may have been limited to the registered medical reports.
The inclusion of patients throughout the years may have
had an impact regarding treatment availability [e.g. angioten-
sin receptor-neprilysin inhibitor (ARNi)] or other
non-controlled confounding factors. We believe the higher
administration of ARNi in TM and PFP groups compared with
UC group should be taken into consideration when evaluating
our results, once we cannot exclude the impact of this con-
founding factor in our results.
We only included patients admitted in a cardiology ward
due to HF decompensation, which may account for a selec-
tion bias of HF patients at higher risk for decompensation. Pa-
tients with HF admitted to internal medicine wards may have
different profiles not evaluated in this study.
Only the first 25 patients were included in the analysis of
this ongoing TM programme. However, it is important to
emphasize this was a real-life study and that the selection
of HF patients for this programme was planned to only tar-
get the population at higher risk of HF re-hospitalization
and mortality.
The restricted 12 month follow-up of this study, similar to
other studies,11,12,16 may not evaluate the feasibility and ef-
fectiveness of TM in the long-term follow-up of HF patients.
Thus, patients’ compliance and motivation could be a prob-
lem in a longer-term follow-up. Additionally, stable patients
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in TM for >12 months may not benefit the same from main-
taining such rigorous and continuous monitoring. These
long-term challenges should be further evaluated in real-life
long-term TM programmes.
Conclusions
In patients with HF with reduced ejection fraction and a re-
cent HF decompensation, remote non-invasive TM reduced
12 month all-cause hospitalization and mortality, as well as
HF-related hospitalizations when compared with usual care.
TM also reduced the number of days lost due to unplanned
hospital admission or death when compared either with usual
care or with an optimized protocol-based follow-up pro-
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